However, we observed that patients with a lower BMI had a higher frequency of CR than those with a higher BMI (66.7 & 81.4% vs 51.3%, p = 0.002). This finding is in contrast to some studies that reported a positive correlation between BMI and CR in patients with DLBCL [23], but in agreement with others that found no association or a negative correlation [24]. The possible mechanisms underlying the relationship between BMI and CR are not clear, but may involve the pharmacokinetics of R-CHOP drugs, the inflammatory status of obese patients, or the tumor microenvironment. This evidence concerns the gene DDIT3 and neoplasm.